WO2012061469A2 - Formes cristallines de pralatrexate - Google Patents

Formes cristallines de pralatrexate Download PDF

Info

Publication number
WO2012061469A2
WO2012061469A2 PCT/US2011/058913 US2011058913W WO2012061469A2 WO 2012061469 A2 WO2012061469 A2 WO 2012061469A2 US 2011058913 W US2011058913 W US 2011058913W WO 2012061469 A2 WO2012061469 A2 WO 2012061469A2
Authority
WO
WIPO (PCT)
Prior art keywords
pralatrexate
ray powder
powder diffraction
diffraction pattern
crystalline form
Prior art date
Application number
PCT/US2011/058913
Other languages
English (en)
Other versions
WO2012061469A3 (fr
Inventor
Paolo Simone Tiseni
Tomislav Biljan
Original Assignee
Sicor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sicor Inc. filed Critical Sicor Inc.
Publication of WO2012061469A2 publication Critical patent/WO2012061469A2/fr
Publication of WO2012061469A3 publication Critical patent/WO2012061469A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention encompasses solid state forms of Pralatrexate, processes for preparation thereof, and pharmaceutical compositions thereof.
  • Pralatrexate (25 -2-[[4-[(li?5)-l-[(2,4-diaminopteridin-6-yl)methyl]but-3- ynyl]benzoyl]amino]pentandioic acid is an anti-cancer drug having the following formula:
  • Pralatrexate is approved for a treatment for patients with relapsed or refractory peripheral T-cell lymphoma. It is an antifolate and acts as an inhibitor of
  • Pralatrexate is disclosed in several documents such as DeGraw et al. (J Med. Chem, 1993, 36, 2228, US 5,354,751, US 6,028,071 B2 and EP 0944389 Bl.
  • Polymorphism the occurrence of different crystal forms, is a property of some molecules and molecular complexes.
  • a single molecule like Pralatrexate, may give rise to a variety of polymorphs having distinct crystal structures and physical properties like melting point, thermal behaviors (e.g. measured by thermogravimetric analysis - "TGA”, or differential scanning calorimetry - “DSC”), X-ray powder diffraction (XRPD) pattern, infrared absorption fingerprint, and solid state nuclear magnetic resonance (NMR) spectrum.
  • TGA thermogravimetric analysis -
  • DSC differential scanning calorimetry -
  • XRPD X-ray powder diffraction
  • NMR solid state nuclear magnetic resonance
  • Discovering polymorphic forms and solvates of a pharmaceutical product can provide materials having desirable processing properties, such as ease of handling, ease of processing, storage stability, and ease of purification or as desirable intermediate crystal forms that facilitate conversion to other polymorphic forms.
  • New polymorphic forms and solvates of a pharmaceutically useful compound can also provide an opportunity to improve the performance characteristics of a
  • the present invention provides solid state forms of Pralatrexate and pharmaceutical compositions comprising said solid state forms and at least one pharmaceutically acceptable excipient.
  • the present invention also encompasses the use of any of the above solid- state forms for the preparation of a pharmaceutical composition.
  • the present invention further encompasses the use of any of the above solid-state forms and pharmaceutical compositions, as a medicament, particularly for the treatment for patients with relapsed or refractory peripheral T-cell lymphoma.
  • the present invention also provides a method of anti-cancer therapy, comprising administering a therapeutically effective amount of at least one of the Pralatrexate solid-state forms of the present invention, or at least one of the above pharmaceutical compositions to a person with relapsed or refractory peripheral T-cell lymphoma.
  • Figure 1 shows an X-ray powder diffractogram of Pralatrexate form A.
  • Figure 2 shows an X-ray powder diffractogram of Pralatrexate form B.
  • Figure 3 shows an X-ray powder diffractogram of Pralatrexate form C.
  • Figure 4 shows an X-ray powder diffractogram of Amorphous Pralatrexate.
  • Figure 5 shows a 13 C NMR spectrum of Pralatrexate form A between 0-200 ppm.
  • Figure 6 shows a 13 C NMR spectrum of Pralatrexate form B between 0-200 ppm.
  • Figure 7 shows a 13 C NMR spectrum of Pralatrexate form C between 0-200 ppm.
  • the present invention addresses a need in the art by providing Pralatrexate in a crystalline form, which is believed to provide significant advantages for making pharmaceutical compositions, as compared to the amorphous form disclosed in the prior art.
  • important factors include chemical stability, solid state stability and "shelf life" of the drug substance.
  • the drug substance, and compositions containing it should be capable of being stored over appreciable periods of time, under conditions such as high humidity without exhibiting a significant change in the active component's physico-chemical characteristics (e.g. its chemical composition, density, hygroscopicity, solubility and rate of dissolution).
  • Crystalline forms of Pralatrexate such as the crystalline forms of the present invention (namely, Forms A, B and C) are believed to provide advantages over the prior art amorphous Pralatrexate in this regard.
  • solid state forms of Pralatrexate of the invention are substantially free of any other polymorphic forms of Pralatrexate, or of specified polymorphic forms of Pralatrexate, respectively.
  • substantially free is meant that the forms of the present invention contain 20% (w/w) or less, 10% (w/w) or less, 5% (w/w) or less, 2% (w/w) or less, particularly 1% (w/w) or less, more particularly 0.5% (w/w) or less, and most particularly 0.2% (w/w) or less of any other polymorphs of Pralatrexate, or of a specified polymorph of Pralatrexate.
  • the polymorphs of Pralatrexate of the invention contain from 1% to 20% (w/w), from 5% to 20% (w/w), or from 5% to 10% (w/w)) of any other polymorphs or of a specified polymorph of Pralatrexate or of an amorphous form of Pralatrexate.
  • the present invention addresses a need in the art by providing new crystalline forms of Pralatrexate that have advantageous properties selected from at least one of: chemical purity, flowability, solubility, dissolution rate, morphology or crystal habit, stability- such as thermal and mechanical stability to polymorphic conversion, stability to dehydration and/or storage stability, low content of residual solvent, a lower degree of hygroscopicity, flowability, and advantageous processing and handling characteristics such as compressibility, and bulk density.
  • a crystal form may be referred to herein as being characterized by graphical data "as shown in,” or “as depicted in” a Figure. Such data include, for example, powder X-ray diffractograms and solid state NMR spectra.
  • a crystal form of Pralatrexate referred to herein as being characterized by graphical data "as shown in,” or “as depicted in” a Figure will thus be understood to include any crystal forms of the Pralatrexate characterized with the graphical data having such small variations, as are well known to the skilled person, in comparison with the Figure.
  • the term "isolated" in reference to any of the Pralatrexate crystalline forms of the present invention corresponds to Pralatrexate crystalline form that is physically separated from the reaction mixture, wherein it was formed.
  • the XRPD measurements are taken using copper Ka radiation wavelength 1.54184 A.
  • a thing e.g., a reaction mixture
  • room temperature (often abbreviated "RT"). This means that the temperature of the thing is close to, or the same as, that of the space, e.g., the room or fume hood, in which the thing is located.
  • room temperature is from about 20°C to about 30°C, or about 22°C to about 27°C, or about 25°C.
  • a process or step may be referred to herein as being carried out
  • overnight This refers to a time interval, e.g., for the process or step, that spans the time during the night, when that process or step may not be actively observed. This time interval is from about 8 to about 20 hours, or about 10-18 hours, typically about 16 hours.
  • reduced pressure refers to a pressure of about 10 mbar to about 50 mbar.
  • anhydrous in relation to crystalline Pralatrexate relates to a crystalline Pralatrexate which contains not more than 1.5% (w/w), or not more than 1% (w/w) of either water or organic solvents (bound and unbound) as measured by TGA or by Karl Fisher titration, for example, Pralatrexate which contains between about 0% to about 1.5% (w/w) or between about 0% to about 1% (w/w) of either water or organic solvents as measured by TGA or by Karl Fisher titration.
  • volume can be used to refer to ml per gram of the corresponding Pralatrexate.
  • a statement that 0.5 g of Pralatrexate is dissolved in ten volumes of a Solvent X would be understood to mean that the 0.5 g of Pralatrexate was dissolved in 5 ml of Solvent X.
  • the present invention comprises a crystalline form of Pralatrexate, designated as Form A.
  • Form A can be characterized by data selected from: an X-ray powder diffraction (XRPD) pattern having peaks at 8.7, 12.3, 15.2, 19.2 and 21.9° 2 ⁇ ⁇ 0.2° 20; an X-ray powder diffraction (XRPD) pattern having peaks at 8.7, 12.3, 14.3, 16.0 and 21.9° 20 ⁇ 0.2° 20; an XRPD pattern substantially as depicted in figure 1; a solid state 13 C NMR spectrum having signals at 25.1, 35.9, 53.2, 122.0 and 146.8 ⁇ 0.2 ppm; a solid state C NMR spectrum as depicted in Figure 5; and combinations thereof.
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • Crystalline Form A of Pralatrexate can be further characterized by data selected from: an XRPD pattern having any one, two, three, four or five additional peaks selected from: 10.9, 14.3, 16.0, 23.3 and 24.3° 2 ⁇ ⁇ 0.2° 2 ⁇ ; and an XRPD pattern having any one, two, three, four or five additional peaks selected from: 10.9, 15.2, 19.2, 23.3 and 24.3° 2 ⁇ ⁇ 0.2° 2 ⁇ .
  • the present invention comprises a crystalline form of Pralatrexate, designated as Form B.
  • Form B can be characterized by data selected from: an XRPD pattern having peaks at 8.9, 11.0, 13.8 and 15.4° 2 ⁇ + 0.2° 2 ⁇ ; an XRPD pattern substantially as depicted in figure 2; a solid state 13 C NMR spectrum having signals at 27.8, 35.4, 68.6, 128.8 and 157.4 ⁇ 0.2 ppm; a solid state 13 C NMR spectrum as depicted in Figure 6; and combinations thereof.
  • Crystalline Form B of Pralatrexate can be further characterized by an X-ray powder diffraction (XRPD) pattern having any one, two, three or four additional peaks selected from: 12.3, 19.2, 21.9 and 24.7° 2 ⁇ ⁇ 0.2° 2 ⁇ .
  • XRPD X-ray powder diffraction
  • the present invention comprises a crystalline form of Pralatrexate, designated as Form C.
  • Form C can be characterized by data selected from: an XRPD pattern having peaks at 8.5, 12.5, 13.1, 22.2, and 24.0° 2 ⁇ ⁇ 0.2° 20; an XRPD pattern having peaks at 8.5, 12.5, 13.1, 22.2, and 29.3° 2 ⁇ ⁇ 0.2° 20; an XRPD pattern substantially as depicted in figure 3; a solid state 13 C NMR spectrum having signals at 42.0, 44.6, 132.5, 153.1 and 180.1 ⁇ 0.2 ppm; a solid state 13 C NMR spectrum as depicted in Figure 7; and combinations thereof.
  • Crystalline Form C of Pralatrexate can be further characterized by data selected from: an XRPD pattern having any one, two, three, four or five additional peaks selected from: 10.8, 15.1, 19.1, 28.5 and 29.3° 2 ⁇ + 0.2° 2 ⁇ ; and an XRPD pattern having any one, two, three, four or five additional peaks selected from: 10.8, 15.1, 19.1, 24.0 and 28.5 ° 20 ⁇ 0.2° 20.
  • the crystalline forms of the present invention are anhydrous forms.
  • the present invention also describes an amorphous form of Pralatrexate.
  • the amorphous form of Pralatrexate can be characterized by an XRPD pattern as depicted in figure 4.
  • the above described forms of Pralatrexate can be used to prepare pharmaceutical compositions by any method known in the art.
  • the present invention further encompasses 1) a pharmaceutical composition comprising at least one of the solid state forms of Pralatrexate as described above, and at least one pharmaceutically acceptable excipient; 2) the use of any one or combination of the above-described solid state forms of Pralatrexate in the manufacture of a pharmaceutical composition, and 3) a method of treating relapsed or refractory peripheral T-cell lymphoma, said method comprising administering a pharmaceutically effective amount of at least one of the solid state forms of
  • Pralatrexate as described above to a subject, e.g., a patient, in need of the treatment.
  • the pharmaceutical composition can be useful for preparing a medicament.
  • the present invention also provides at least one of the solid state forms of Pralatrexate as described above for use as a medicament.
  • the pharmaceutical composition may be in a form of a solution.
  • the scanning parameters were: range: 3-40 degrees two-theta; scan mode: continuous scan; step size: 0.0167°; and time per step: 37 sec.
  • NMR spectra of solid samples were recorded on a Varian NMR System 600 MHz NMR spectrometer equipped with a 3.2 mm NB Double Resonance HX MAS Solids Probe. Larmor frequency of carbon nuclei was 150.79 MHz. The C CP- MAS NMR spectra were externally referenced to the methyl groups of
  • the pulse sequence used for acquiring spectra was a standard cross-polarization MAS pulse sequence with high-power proton decoupling during acquisition. Repetition delay was 5 s and the number of scans was between 3200 and 9000.
  • Example 1 Preparation of Pralatrexate according to U.S. Patent No. 6,028,071, example 1
  • FIG. 4 of U.S. Patent No. 6,028,071 shows a synthetic scheme useful in preparing pralatrexate.
  • Example 1A Compound 2 of Figure 4 of US 6,028,071
  • a mixture of 60% NaH in oil dispersion (1.06 g, 26.5 mmol) in 18 mL of sieve-dried THF was cooled to 0°C.
  • the cold mixture was treated with a solution of homoterephthalic acid dimethyl ester (5.0 g, 24 mmol.; compound 1 in FIG. 4 of US 6,0280,71) in dry THF (7 mL), and the mixture was stirred for 1 hour at 0°C.
  • Propargyl bromide (26.4 mmol) was added, and the mixture was stirred at 0°C for an additional 1 hour, and then at room temperature for 16 hours.
  • the resulting mixture was treated with 2.4 mL of 50% acetic acid and then poured into 240 mL of water.
  • the mixture was extracted with ether (2 times; 150 mL). The ether extracts were combined, dried over Na 2 S04, and concentrated to an orange-yellow oil.
  • Example IB 10-Propargyl-10-carbomemoxy-4-deoxy-4-arnino-10-deazapteroic acid methyl ester (compound 3 in Figure 4 of US 6,028,071)
  • a mixture was formed by combining 0.36 g of NaH (9 mmol, 60% dispersion in oil) with 10 mL of dry DMF, and cooling the mixture to 0-5°C.
  • the cold mixture was treated dropwise with a solution of the product of the first reaction (compound 2 from Example 1 A) (2.94 g, 12 mmol) in 10 mL dry DMF, and then stirring this mixture at 0°C for 30 minutes.
  • a solution of 2,4,diamino-6-(bromomethyl)pteridine hydrobromide-0.2 2-propanol (1.00 g, 2.9 mmol) in 10 mL dry DMF was added dropwise while the temperature was maintained near -25°C.
  • Example 1C Compound 4 of Figure 4 of US 6,028,071
  • Example ID 10-Propargyl-4-deoxy-4-amino-10-deazapteroic acid (compound 5 of Figure 4 of US 6,028,071)
  • Example IE 10-Propargyl-lO-deazaaminopterin dimethyl ester (compound 6 of Figure 4 of US 6,028,071
  • the crude product (350 mg) was purified by silica gel chromatography eluting with CHCl 3 ⁇ MeOH (10:1) containing triethylamine (0.25% by volume) to recover 165 mg of 10-propargyl-lO-deazaaminopterin dimethyl ester (compound 6 of Figure 4 of US 6,028,071, 50% yield), which was homogeneous by TLC (CHCb-MeOH 5:1).
  • Amorphous pralatrexate 400 mg, purity 96%) was dissolved in formamide at room temperature (1 mL, 2.5 Vol.). The solution was poured into water at room temperature (10 mL, 25 Vol.), resulting in the formation of a precipitate. The precipitate was filtered off and dried in a vacuum drying oven at 35°C under vacuum for 18 h, furmshing pralatrexate Form A (200 mg, 50% yield, 96% purity).
  • Amorphous pralatrexate (200 mg, purity 96% %) was suspended in MeOH (2 mL, 10 Vol.), and the slurry was stirred at room temperature. After 24 h of stirring, the solid was filtered off and dried in a vacuum drying oven at 35°C under vacuum for 18 h, furrmhing pralatrexate Form B (118 mg, 59% yield, 96% purity).
  • Amorphous pralatrexate (200 mg, purity 96%) was suspended in MeOH (2 mL, 10 Vol.) and the slurry was heated up to 50 °C. After 24 h the solid was filtered off and dried in a vacuum drying oven at 35°C under vacuum, furnishing pralatrexate Form B (96 mg, 48% yield, 96% purity).
  • pralatrexate A solution of pralatrexate in water was prepared as described in example IF above (according to U.S. Patent No. 6,028,071, example 1). Pralatrexate was precipitated by addition of aq. HC1 10 % to adjust to pH 4.5. The solid was filtered off and dried in a vacuum drying oven at 35°C under vacuum, furnishing pralatrexate as a pale yellow solid.
  • Example 6 Preparation of crystalline Pralatrexate Form A:
  • Amorphous pralatrexate 400 mg, purity 98.5%) was suspended in water (4 mL, 10 Vol.) pre-heated at 50 °C, and the slurry was stirred for 4 h at 50°C. The solid was then filtered off and dried in a vacuum drying oven at 45 °C under vacuum for 18h, furnishing pralatrexate form A (305 mg, 76% yield, 98.5% purity).
  • Amorphous pralatrexate 400 mg, purity 98.5%) was suspended in MeOH (4 mL, 10 Vol.) pre-heated at 50 °C, and the slurry was stirred for 16 h at 50 °C. The solid was then filtered off and dried in a vacuum drying oven at 45 °C under vacuum for 18 h, furnishing pralatrexate form B (250 mg, 63% yield, 97% purity).
  • Amorphous pralatrexate 400 mg, purity 98.5%) was suspended in a mixture of water (2 mL, 5 Vol.) and MeOH (2 mL, 5 Vol.) pre-heated at 50 °C, and the slurry was stirred for 2 h at 50 °C. The solid was filtered off and dried in a vacuum drying oven at 45 °C under vacuum for 18 h, furnishing pralatrexate form C (320 mg, 80% yield, 98.5% purity).
  • Amorphous pralatrexate (200 mg, purity 96%) was suspended in MeOH (2 mL, 10 Vol.) Upon heating at 50 °C, water was added (2 mL, 10 Vol.) and the resulting slurry was kept at 50 °C for 24 h. The solid was then filtered off and dried in a vacuum drying oven at 35°C under vacuum, furnishing pralatrexate Form C (96 mg, 48% yield, 96% purity).

Abstract

La présente invention concerne des formes cristallines de pralatrexate, en particulier la forme A, la forme B et la forme C, des compositions pharmaceutiques comprenant une forme cristalline de pralatrexate et au moins un excipient pharmaceutiquement acceptable, et des procédés d'utilisation d'une des compositions pour le traitement du lymphome à lymphocytes T périphériques récurrent ou réfractaire.
PCT/US2011/058913 2010-11-02 2011-11-02 Formes cristallines de pralatrexate WO2012061469A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40926310P 2010-11-02 2010-11-02
US61/409,263 2010-11-02

Publications (2)

Publication Number Publication Date
WO2012061469A2 true WO2012061469A2 (fr) 2012-05-10
WO2012061469A3 WO2012061469A3 (fr) 2013-05-02

Family

ID=46025080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/058913 WO2012061469A2 (fr) 2010-11-02 2011-11-02 Formes cristallines de pralatrexate

Country Status (1)

Country Link
WO (1) WO2012061469A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177713A1 (fr) * 2012-05-31 2013-12-05 Alphora Research Inc. Procédé de préparation d'un agent antifolate
WO2014020553A1 (fr) 2012-08-03 2014-02-06 Fresenius Kabi Oncology Ltd. Sels de pralatrexate
CN104418859A (zh) * 2013-09-09 2015-03-18 上海医药工业研究院 普拉曲沙的晶型、含其的药物组合物及其制备方法和应用
WO2014068599A3 (fr) * 2012-11-02 2015-03-19 Hetero Research Foundation Procédé pour le pralatrexate
CN104628727A (zh) * 2013-11-07 2015-05-20 正大天晴药业集团股份有限公司 一种普拉曲沙的晶型及其制备方法
CN105272983A (zh) * 2014-06-12 2016-01-27 连云港润众制药有限公司 一种高纯度普拉曲沙固体及其制备方法
CN108069971A (zh) * 2016-11-18 2018-05-25 鲁南制药集团股份有限公司 一种普拉曲沙中间体的精制方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354751A (en) 1992-03-03 1994-10-11 Sri International Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis
US6028071A (en) 1996-07-17 2000-02-22 Sloan-Kettering Institute For Cancer Research Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354751A (en) 1992-03-03 1994-10-11 Sri International Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis
US6028071A (en) 1996-07-17 2000-02-22 Sloan-Kettering Institute For Cancer Research Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors
EP0944389B1 (fr) 1996-07-17 2008-09-10 Sloan-Kettering Institute For Cancer Research Compositions purifiees de 10-propargyl-10-deazaaminopterine et leur methodes d'utilisation pour le traitement de tumeurs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DEGRAW ET AL., J. MED. CHEM, vol. 36, 1993, pages 2228

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177713A1 (fr) * 2012-05-31 2013-12-05 Alphora Research Inc. Procédé de préparation d'un agent antifolate
WO2014020553A1 (fr) 2012-08-03 2014-02-06 Fresenius Kabi Oncology Ltd. Sels de pralatrexate
WO2014068599A3 (fr) * 2012-11-02 2015-03-19 Hetero Research Foundation Procédé pour le pralatrexate
US9783542B2 (en) 2012-11-02 2017-10-10 Hetero Research Foundation Process for pralatrexate
CN104418859A (zh) * 2013-09-09 2015-03-18 上海医药工业研究院 普拉曲沙的晶型、含其的药物组合物及其制备方法和应用
CN104418859B (zh) * 2013-09-09 2016-06-22 上海医药工业研究院 普拉曲沙的晶型、含其的药物组合物及其制备方法和应用
CN104628727A (zh) * 2013-11-07 2015-05-20 正大天晴药业集团股份有限公司 一种普拉曲沙的晶型及其制备方法
CN105272983A (zh) * 2014-06-12 2016-01-27 连云港润众制药有限公司 一种高纯度普拉曲沙固体及其制备方法
CN105272983B (zh) * 2014-06-12 2021-01-15 连云港润众制药有限公司 一种高纯度普拉曲沙固体及其制备方法
CN108069971A (zh) * 2016-11-18 2018-05-25 鲁南制药集团股份有限公司 一种普拉曲沙中间体的精制方法
CN108069971B (zh) * 2016-11-18 2021-02-12 鲁南制药集团股份有限公司 一种普拉曲沙中间体的精制方法

Also Published As

Publication number Publication date
WO2012061469A3 (fr) 2013-05-02

Similar Documents

Publication Publication Date Title
US11149017B2 (en) Solid state forms of apalutamide
WO2012061469A2 (fr) Formes cristallines de pralatrexate
US11667646B2 (en) Solid state forms of rucaparib and of rucaparib salts
US11332467B2 (en) Solid state forms of palbociclib dimesylate
EP3205653B1 (fr) Forme cristalline de bisulfate d'inhibiteur de jak et son procédé de préparation
EP2753616A1 (fr) Formes cristallines de di-maléate d'afatinib
EP3344607B1 (fr) Formes à l'état solide de selexipag
EP3672968B1 (fr) Forme à l'état solide du succinate de ribociclib
WO2013090490A1 (fr) Sels de tofacitinib
US20210387952A1 (en) Solid state forms of daprodustat and process for preparation thereof
EP3430004B1 (fr) Formes solides de sels de nilotinib
US20180273499A1 (en) Salts and solid state forms of vortioxetine
US20220002302A1 (en) Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
WO2012071425A1 (fr) Formes à l'état solide de bésylate de sorafénib et procédés de préparation
WO2013181251A9 (fr) Sel de chlorhydrate de crizotinib sous forme cristalline
US11339164B2 (en) Crystalline form E1 of larotrectinib ethanesulfonate
WO2024069574A1 (fr) Formes à l'état solide de denifanstat
WO2023164255A1 (fr) Formes cristallines de trilaciclib et de sels de trilaciclib
WO2022081502A1 (fr) Formes à l'état solide de lorécivivint
WO2023043869A1 (fr) Formes à l'état solide de citrate d'ipatasertib
WO2019167068A1 (fr) Nouveaux polymorphes de succinate de ribociclib
WO2017035170A1 (fr) Formes à l'état solide de maléate de cédiranib
WO2011091142A2 (fr) Formes cristallines et amorphes de pamoate d'olanzapine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11838727

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11838727

Country of ref document: EP

Kind code of ref document: A2